Beacon Therapeutics Secures $170M Series B Financing to Advance AAV Gene Therapy for X-Linked Retinitis Pigmentosa
Beacon Therapeutics
Ophthalmology Gene Therapy Technology Researcher
This round of financing was led by Forbion, with continued participation from Syncona and Oxford Science Enterprises. Additionally, TCGX and Advent Life Sciences made their first investments in the company. This financing brings the total amount raised by the company since its establishment to $290 million. The company, headquartered in London with a branch in Massachusetts, USA,Founded in 2023, completed a $120 million Series A financing round in June of the same year and acquired the ophthalmic gene therapy company Applied Genetic Technologies Corporation (AGTC).
BeaconFocus onAdeno-Associated Virus (AAV) VectorDevelopment of treatments for retinal diseasesNew GenerationGene Therapy. The company will use the new funds to continue the research and development of its core product, AGTC-501, which uses AAV2 as a vector and has an indication forX-linked Retinitis Pigmentosa (XLRP),Currently in Phase II/III clinical trials. The uniqueness of AGTC-501 lies in its ability to express the full-length RPGR protein, which can repair all photoreceptor damage caused by XLRP. In addition, Beacon Therapeutics plans to use part of the funds to conduct a Phase I/II trial for its dry age-related macular degeneration project.
In addition, as part of this financing, Beacon expanded its board members, including Dr. Dmitrij Hristodorov and Wouter Joustra from Forbion, as well as Cariad Chester, Managing Partner of TCGX.
Beacon Therapeutics' CEO David Fellows stated that the company will focus on advancing its ophthalmology gene therapy pipeline. The addition of new board members and funding will support the continued progress of the company’s pipeline, accelerating the clinical development and commercialization of AGTC-501.
Elisa Petris, Partner at Syncona and Board Member of Beacon Therapeutics, said that Syncona’s continued support for Beacon reflects the capability of the company’s leadership team and innovation in developing gene therapies for retinal diseases. This financing round and collaboration with high-quality investors will enable Beacon Therapeutics to accelerate the advancement of its treatment programs for both rare and common eye conditions.
E.N.D
Previous article recommendations:
Ten Companies in China Complete New Round of Financing, Focusing on Cell and Gene Therapy Fields
Over $1 Billion! Leading CDMO Receives Another Major Order
Beacon Therapeutics Appoints Dr. Zhang Xinhua as Vice President of Quality
Legend Biotech Announces Positive Phase 3 Results for CAR-T Therapy
Beacon Therapeutics Completes Nearly RMB100 Million Series A Financing, Led by SDIC Venture Capital
Moom Bio Completes 300 Million Yuan C+ Round Financing
Beacon Therapeutics Announces the Appointment of Ms. Lijuan Chen as Interim CEO
A Gene Therapy Company in Hangzhou Officially Opens
Beacon Therapeutics' Innovative Solid Tumor CAR-T Drug Approved for Clinical Trials
China's First Stem Cell New Drug Submits for Market Approval and Receives Priority Review
CSPC's First mRNA-LNP-Based CAR-T Cell Injection Approved for Clinical Trials
Nanjing Airport Opens Import and Export Channel for CAR-T Cell Therapy Drugs
Long-term Follow-up Data of Beacon Therapeutics' First AAV Gene Therapy Drug Published
China's First mRNA-LNP Technology Group Standard Draft for Comment, Involving Cell Therapy
Beacon Therapeutics Secures $100 Million in Series C Financing, Focusing on “AI + Drug Delivery”
Official Signing! A Biomedical Innovation Company Settles in Minhang
Priced at $3.2 Million, First DMD Gene Therapy Receives Full FDA Approval!